Latest news with #SGMO
Yahoo
13-05-2025
- Business
- Yahoo
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sangamo Therapeutics Inc (NASDAQ:SGMO) signed a significant license agreement with Eli Lilly, potentially worth up to $1.4 billion in milestone payments. The company is advancing its neurology pipeline, with preparations for a Phase 1/2 study of ST 503 for chronic neuropathic pain. Sangamo has achieved important clinical and regulatory milestones for its Fabry disease program, with a pivotal data readout expected soon. The company has reduced non-GAAP operating expenses by 50% year-on-year, demonstrating financial discipline. Sangamo is actively engaging in promising business development discussions, indicating ongoing interest in its technology platforms. Sangamo Therapeutics Inc (NASDAQ:SGMO) requires additional capital to fund its operations and achieve proof of concept in its programs. The company is reliant on securing a commercial partnership for its Fabry disease program to ensure long-term funding. There is uncertainty regarding the statistical analysis plan for the EGFR data, which is crucial for regulatory submissions. The company faces challenges in the broader macroeconomic landscape, including potential impacts from drug pricing discussions. Sangamo's immediate cash runway is limited, necessitating a recent equity offering to extend its financial runway. Warning! GuruFocus has detected 7 Warning Signs with SGMO. Q: Could you provide more color on what exactly you plan to show in the top line EGFR data? Will you show just the EGFR slope or other quality of life endpoints? Also, will there be an NHS analysis to contextualize the improvements in EGFR? A: We will share the updated mean EGFR slope in the top line data and comment on additional information at a later date. We have agreed with the FDA on our statistical analysis plan, but we are not commenting on specifics at this time. Q: How many potential partners are you currently in conversations with regarding a potential Fabry partnership, and what can you tell us about those discussions? A: We are in discussions with multiple potential partners. The recent Type B meeting with the FDA was helpful, providing a clear path for CMC, which is crucial for any gene therapy BLA and approval. Q: Given the current administration's concern around drug pricing, how do you think that will impact gene therapy uptake and pricing in the US and abroad? A: There is a long way to go in discussions around drug pricing. The pharmaceutical industry is important in America, and BIO will be having detailed conversations with the administration to find a productive way forward. Q: Do you still plan to file based on 52-week EGFR data for Fabry, and is static versus baseline required for EGFR? A: Yes, we are pursuing the agreement with the FDA to use 52-week EGFR data for the entire patient population in the phase one study. We have collected all the data and expect to share the topline data at the end of the quarter, which will be the basis for our BLA. Q: Are the patients who were on ERT still off ERT, or were there any relapses? A: Yes, all 18 patients who started on ERT out of our 32 patients are still off ERT. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
13-05-2025
- Business
- Business Insider
Sangamo reports Q1 EPS (14c) vs (27c) last year
Reports Q1 revenue $6.44M, consensus $7.42M. 'This quarter we continued to advance our promising neurology genomic medicine pipeline and are pleased to have signed our third STAC-BBB license agreement, reinforcing that Sangamo (SGMO) is a collaborator of choice for neurotropic capsids,' said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. 'We achieved significant clinical and regulatory derisking milestones in our Fabry disease program and raised additional capital through business development and other means, to provide additional runway to secure a potential Fabry partner. With our neuropathic pain program ready to enter the clinic, we look forward to dosing the first patients with our epigenetic regulation technology, which we hope will usher in a new era in chronic pain treatment.' Protect Your Portfolio Against Market Uncertainty
Yahoo
13-05-2025
- Business
- Yahoo
Sangamo: Q1 Earnings Snapshot
RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Monday reported a loss of $30.6 million in its first quarter. The Richmond, California-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share. The drug developer posted revenue of $6.4 million in the period, which also missed Street forecasts. Three analysts surveyed by Zacks expected $9.2 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on SGMO at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
12-05-2025
- Business
- Washington Post
Sangamo: Q1 Earnings Snapshot
RICHMOND, Calif. — RICHMOND, Calif. — Sangamo Therapeutics Inc. (SGMO) on Monday reported a loss of $30.6 million in its first quarter. The Richmond, California-based company said it had a loss of 14 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share.
